retatrutide type 2 diabetes phase 2 trial 2024 🚨Breaking: Retatrutide's first 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending Pharmacological therapies for type 2

The latest #TheActuary article breaks down the policy developments and trends worth knowing: To view or add a comment, sign in GLP-1s have added a new layer to work that was already complex

MOTS-c is studied in metabolic health, exercise capacity, body composition, aging, bone metabolism, and inflammation

Thanks to this enhanced delivery and absorption, nutrients delivered in liposomal form offer superior absorption and bioavailability.

Liraglutide, the active comparator, was initiated at 0.6 mg daily and titrated weekly up to 3.0 mg

Classification and clinical features of adverse drug reactions in patients with ulcerative colitis treated with 5-aminosalicylate acid: a single-center, observational study